Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 27;22(9):4590.
doi: 10.3390/ijms22094590.

State-of-Art of Cellular Therapy for Acute Leukemia

Jong-Bok Lee  1 , Daniel Vasic  1   2 , Hyeonjeong Kang  1   2 , Karen Kai-Lin Fang  1   2 , Li Zhang  1   2   3
Affiliations
Review

State-of-Art of Cellular Therapy for Acute Leukemia

Jong-Bok Lee et al. Int J Mol Sci. .

Abstract

With recent clinical breakthroughs, immunotherapy has become the fourth pillar of cancer treatment. Particularly, immune cell-based therapies have been envisioned as a promising treatment option with curative potential for leukemia patients. Hence, an increasing number of preclinical and clinical studies focus on various approaches of immune cell-based therapy for treatment of acute leukemia (AL). However, the use of different immune cell lineages and subsets against different types of leukemia and patient disease statuses challenge the interpretation of the clinical applicability and outcome of immune cell-based therapies. This review aims to provide an overview on recent approaches using various immune cell-based therapies against acute B-, T-, and myeloid leukemias. Further, the apparent limitations observed and potential approaches to overcome these limitations are discussed.

Keywords: CAR-T cell; DNT cell; NK cell; acute leukemia; adoptive cellular therapy.

PubMed Disclaimer

Conflict of interest statement

L.Z. and J.-B.L. are co-inventors on several DNT cell technology related patents and intellectual properties (IPs). D.V. and H.K. are co-inventors on DNT cell technology related patents.

Figures

Figure 1
Figure 1
Challenges of CAR-T therapy for T-ALL.
Figure 2
Figure 2
Various approaches to improve the persistence and therapeutic efficacy of adoptive cellular therapy.
Figure 3
Figure 3
Current challenges using ACT to treat acute leukemia.
See this image and copyright information in PMC

References

    1. Dores G.M., Devesa S.S., Curtis R.E., Linet M.S., Morton L.M. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2012;119:34–43. doi: 10.1182/blood-2011-04-347872. - DOI - PMC - PubMed
    1. Terwilliger T., Abdul-Hay M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577. doi: 10.1038/bcj.2017.53. - DOI - PMC - PubMed
    1. Dohner H., Estey E., Grimwade D., Amadori S., Appelbaum F.R., Buchner T., Dombret H., Ebert B.L., Fenaux P., Larson R.A., et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447. doi: 10.1182/blood-2016-08-733196. - DOI - PMC - PubMed
    1. Guru Murthy G.S., Pondaiah S.K., Abedin S., Atallah E. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. Leuk. Lymphoma. 2019;60:1171–1178. doi: 10.1080/10428194.2018.1522442. - DOI - PubMed
    1. Dohner H., Weisdorf D.J., Bloomfield C.D. Acute Myeloid Leukemia. N. Engl. J. Med. 2015;373:1136–1152. doi: 10.1056/NEJMra1406184. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources